These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 20633748)
1. Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment. Holtzheimer PE; Veitengruber J; Wang CC; Krows M; Thiede H; Wald A; Roy-Byrne P Gen Hosp Psychiatry; 2010; 32(4):426-32. PubMed ID: 20633748 [TBL] [Abstract][Full Text] [Related]
2. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. Golub ET; Latka M; Hagan H; Havens JR; Hudson SM; Kapadia F; Campbell JV; Garfein RS; Thomas DL; Strathdee SA; J Urban Health; 2004 Jun; 81(2):278-90. PubMed ID: 15136661 [TBL] [Abstract][Full Text] [Related]
3. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection. Mahajan S; Avasthi A; Grover S; Chawla YK J Psychosom Res; 2014 Aug; 77(2):109-15. PubMed ID: 25077851 [TBL] [Abstract][Full Text] [Related]
4. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734 [TBL] [Abstract][Full Text] [Related]
5. [Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report]. Małyszczak K; Inglot M; Pawłowski T; Czarnecki M; Rymer W; Andrzej K Psychiatr Pol; 2006; 40(4):799-808. PubMed ID: 17068951 [TBL] [Abstract][Full Text] [Related]
6. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Ebner N; Wanner C; Winklbaur B; Matzenauer C; Jachmann CA; Thau K; Fischer G Addict Biol; 2009 Apr; 14(2):227-37. PubMed ID: 19291011 [TBL] [Abstract][Full Text] [Related]
7. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. Reichenberg A; Gorman JM; Dieterich DT AIDS; 2005 Oct; 19 Suppl 3():S174-8. PubMed ID: 16251815 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Schaefer M; Mauss S Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716 [TBL] [Abstract][Full Text] [Related]
9. Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. Klein MB; Lee T; Brouillette MJ; Sheehan NL; Walmsley S; Wong DK; Conway B; Hull M; Cooper C; Haidar S; Vezina S; Annable L; Young S; Zubyk W; Singer J HIV Clin Trials; 2014; 15(4):161-75. PubMed ID: 25143025 [TBL] [Abstract][Full Text] [Related]
10. Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. Grassi L; Mondardini D; Pavanati M; Sighinolfi L; Serra A; Ghinelli F J Affect Disord; 2001 May; 64(2-3):195-202. PubMed ID: 11313086 [TBL] [Abstract][Full Text] [Related]
11. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Nguyen OK; Dore GJ; Kaldor JM; Hellard ME; Int J Drug Policy; 2007 Oct; 18(5):447-51. PubMed ID: 17854736 [TBL] [Abstract][Full Text] [Related]
12. Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Weiss JJ; Gorman JM Curr HIV/AIDS Rep; 2006 Nov; 3(4):176-81. PubMed ID: 17032577 [TBL] [Abstract][Full Text] [Related]
13. Validation of the Polish version of the Beck Depression Inventory in patients with epilepsy. Wiglusz MS; Landowski J; Michalak L; Cubała WJ Epilepsy Behav; 2017 Dec; 77():58-61. PubMed ID: 29111504 [TBL] [Abstract][Full Text] [Related]
14. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Comai S; Cavalletto L; Chemello L; Bernardinello E; Ragazzi E; Costa CV; Bertazzo A Pharmacol Res; 2011 Jan; 63(1):85-92. PubMed ID: 20940053 [TBL] [Abstract][Full Text] [Related]
15. Interferon-induced depression in patients with hepatitis C: an epidemiologic study. Medeiros LP; Kayo M; Medeiros RB; Lima MB; Mello CE Rev Assoc Med Bras (1992); 2014; 60(1):35-9. PubMed ID: 24918850 [TBL] [Abstract][Full Text] [Related]
16. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation. Chapman J; Oser M; Hockemeyer J; Weitlauf J; Jones S; Cheung R Am J Gastroenterol; 2011 Dec; 106(12):2123-32. PubMed ID: 21826113 [TBL] [Abstract][Full Text] [Related]
17. What is the best screening test for depression in chronic spinal pain patients? Choi Y; Mayer TG; Williams MJ; Gatchel RJ Spine J; 2014 Jul; 14(7):1175-82. PubMed ID: 24225008 [TBL] [Abstract][Full Text] [Related]
18. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Lotrich FE; Ferrell RE; Rabinovitz M; Pollock BG Clin Neuropharmacol; 2010 Jul; 33(4):191-7. PubMed ID: 20661026 [TBL] [Abstract][Full Text] [Related]
19. Factor structure and diagnostic efficiency of the BDI-II in treatment-seeking substance users. Seignourel PJ; Green C; Schmitz JM Drug Alcohol Depend; 2008 Mar; 93(3):271-8. PubMed ID: 18093749 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]